A phase I study of LBH589 [panobinostat] in combination with capecitabine ± lapatinib.
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2015
At a glance
- Drugs Panobinostat (Primary) ; Capecitabine; Lapatinib
- Indications Breast cancer; Male breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2013 Planned end date changed from 1 Nov 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 14 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.